Yet one question rises beneath the excitement: What exactly are patients losing fat, muscle, or water
Clinical trials have shown that semaglutide and liraglutide are generally well tolerated, with gastrointestinal disorders being the most commonly reported AEs, including nausea, diarrhea, vomiting, and constipation, leading to dose reduction or temporary treatment interruption in 12.5% of study participants [40,41,42]
Yes, anti-nausea medications can be used alongside tirzepatide when dietary and lifestyle changes are not enough
Medicaid: Most states cover Ozempic for diabetes, with copays typically between $1 and $5 , though weight loss coverage is very limited
Retatrutide is a triple agonist, while Tirzepatide is a dual agonist
It has been proposed that Met might reduce the activity of pyruvate kinase, which could inhibit glycolysis and lactate accumulation